Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for Aclaris Therapeutics (ACRS) over the last 7 years, with Sep 2025 value amounting to $11.5 million.

  • Aclaris Therapeutics' Gains from Investment Securities rose 77.72% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 77.72%. This contributed to the annual value of $6.7 million for FY2024, which is 4.71% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Gains from Investment Securities stood at $11.5 million for Q3 2025, which was up 663.63% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Gains from Investment Securities peaked at $11.5 million during Q3 2025, and registered a low of -$26.3 million during Q4 2023.
  • Over the past 3 years, Aclaris Therapeutics' median Gains from Investment Securities value was $1.7 million (recorded in 2023), while the average stood at $1.3 million.
  • Within the past 5 years, the most significant YoY rise in Aclaris Therapeutics' Gains from Investment Securities was 672.13% (2023), while the steepest drop was 470.42% (2023).
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Gains from Investment Securities stood at $2.2 million in 2021, then spiked by 222.73% to $7.1 million in 2022, then plummeted by 470.42% to -$26.3 million in 2023, then spiked by 95.06% to -$1.3 million in 2024, then skyrocketed by 77.72% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $1.5 million for Q2 2025, and $300,000 during Q1 2025.